Expenses for Clinical Trials Outside Approved Facility Eligible for Deduction &D

The Tribunal allowed the appeal, ruling that expenses on clinical trials conducted outside the approved in-house R&D facility are eligible for weighted deduction under Section 35(2AB). The Tribunal emphasized that prior to the 1.7.2016 amendment, DSIR's Form 3CL did not quantify eligible expenses, and the AO must accept DSIR's certification. The Tribunal's interpretation of "in-house" and reliance on judicial precedents underscored the broader scope of Section 35(2AB) to include necessary external activities integral to the R&D process.

---

---

Issues Involved:
1. Eligibility of weighted deduction under Section 35(2AB) for expenses on clinical trials conducted outside the approved in-house R&D facility.
2. Interpretation of the term "in-house" in Section 35(2AB).
3. Validity of Form 3CL issued by the Department of Scientific and Industrial Research (DSIR) for quantifying eligible expenses.
4. Jurisdiction of the Assessing Officer (AO) versus DSIR in determining eligible R&D expenses.

Detailed Analysis:

1. Eligibility of Weighted Deduction under Section 35(2AB) for Expenses on Clinical Trials Conducted Outside the Approved In-House R&D Facility:
The core issue was whether expenses on clinical trials conducted by external agencies outside the approved in-house R&D facility are eligible for weighted deduction under Section 35(2AB). The AO had disallowed the weighted deduction for these expenses, allowing only a 100% deduction under Section 35(1). The CIT(A) upheld this disallowance, interpreting that Section 35(2AB) intended to incentivize only in-house R&D activities. The Tribunal, however, referenced the Cadila Healthcare Ltd. case, which held that clinical trials, even when conducted outside the approved facility, are integral to scientific research and thus eligible for weighted deduction under Section 35(2AB).

2. Interpretation of the Term "In-House" in Section 35(2AB):
The Tribunal examined the term "in-house" and concluded that it does not strictly confine the research activities within the physical premises of the company. The Tribunal interpreted that the term "on in-house research and development facility" allows for some external activities, such as clinical trials, as long as they are an integral part of the in-house R&D process. This interpretation was supported by the Explanation to Section 35(2AB), which includes clinical trials as part of scientific research.

3. Validity of Form 3CL Issued by DSIR for Quantifying Eligible Expenses:
The DSIR's Form 3CL, which quantifies eligible R&D expenses, was another point of contention. The AO and CIT(A) relied on this form to disallow the expenses on clinical trials conducted outside the approved facility. The Tribunal noted that prior to the amendment effective from 1.7.2016, Form 3CL did not quantify the eligible expenses but was merely an intimation of approval. Various Tribunal decisions, including Cummins India Ltd. and Force Motors, supported the view that the quantification requirement by DSIR was introduced only after the amendment and should not affect claims for periods before this date.

4. Jurisdiction of the Assessing Officer (AO) versus DSIR in Determining Eligible R&D Expenses:
The Tribunal referenced the Karnataka High Court's decision in Tejas Networks Ltd., which held that the AO cannot scrutinize the DSIR's certification of R&D expenses. The prescribed authority (DSIR) has the final say in certifying the R&D expenses, and the AO must accept this certification. This principle further supported the Tribunal's decision to allow the weighted deduction for clinical trial expenses, as certified by DSIR in Form 3CL.

Conclusion:
The Tribunal allowed the appeal, ruling that the expenses on clinical trials conducted outside the approved in-house R&D facility are eligible for weighted deduction under Section 35(2AB). The Tribunal emphasized that prior to the amendment effective from 1.7.2016, DSIR's Form 3CL did not quantify eligible expenses, and the AO must accept the DSIR's certification. The Tribunal's interpretation of "in-house" and reliance on judicial precedents underscored the broader scope of Section 35(2AB) to include necessary external activities integral to the R&D process.

---